Genmab Total Non-Operating Income/Expense 2019-2024 | GMAB

Genmab total non-operating income/expense for the twelve months ending September 30, 2024 was $0.038B, a 130.84% decline year-over-year.

  • Genmab annual total non-operating income/expense for 2023 was $0.046B, a 52.21% decline from 2022.
  • Genmab annual total non-operating income/expense for 2022 was $0.096B, a 37.47% decline from 2021.
  • Genmab annual total non-operating income/expense for 2021 was $0.154B, a 345.03% decline from 2020.

Genmab Total Non-Operating Income/Expense 2019-2024 | GMAB

  • Genmab annual total non-operating income/expense for 2023 was $0.046B, a 52.21% decline from 2022.
  • Genmab annual total non-operating income/expense for 2022 was $0.096B, a 37.47% decline from 2021.
  • Genmab annual total non-operating income/expense for 2021 was $0.154B, a 345.03% decline from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$158.3B
Bristol Myers Squibb (BMY)$119.4B
Vertex Pharmaceuticals (VRTX)$116.1B
Gilead Sciences (GILD)$112.4B
CSL (CSLLY)$87.2B
Regeneron Pharmaceuticals (REGN)$81.1B
GSK (GSK)$70.4B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$31.6B
BioNTech SE (BNTX)$27.1B
Biogen (BIIB)$23B
Illumina (ILMN)$22.2B
BeiGene (BGNE)$18.6B
Moderna (MRNA)$15.8B
Incyte (INCY)$13.8B
Insmed (INSM)$13.1B
BioMarin Pharmaceutical (BMRN)$12.2B
Bio-Techne Corp (TECH)$11.3B
Vaxcyte (PCVX)$11B
Sarepta Therapeutics (SRPT)$10.9B
Exelixis (EXEL)$10.2B
Exact Sciences (EXAS)$9.8B
QIAGEN (QGEN)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$9.3B
Intra-Cellular Therapies (ITCI)$9.1B
Repligen (RGEN)$8B
Ascendis Pharma (ASND)$7.9B
Legend Biotech (LEGN)$7.5B